Fig. 1

Treatment with a combination of sulbactam and doxorubicin reduced the viability of breast cancer cells. a MCF10A, b BT474, c MCF-7, d MDA-MB-231, e MDA-MB-361, f MDA-MB-435, g MDA-MB-453, h MDA-MB-468, i T47D. Data are expressed as the percentage of cell viability compared with the negative control in which the cell viability was assumed to be 100%. Reported values represent mean ± SD of at least three independent experiments. *p < 0.05 and **p < 0.01 versus only Dox-treated cells. Sul sulbactam, Dox doxorubicin, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, SD standard deviation